Abstract
Background: Increasing competition generally decreases product prices, but in the case of pharmaceuticals, this is only beneficial if competitor products are therapeutically equivalent. This study analyzed drug samples from countries with emerging economies, assessing them for basic quality.Results: Removing all obvious and suspected counterfeit products and degraded products, 1912 samples remained. 3.8% failed basic quality control tests performed with the Global Pharma Health Fund e.V. Minilab. 5.2% failed product authentication by raman spectrometer. Africa has a greater problem with substandard products than any other location.Conclusions: Since all of the sampled drugs are used to treat potentially lethal infections, it is important that the threat of these substandard products be more widely recognized.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
